AXIS: A trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke

Stroke

Volumn 41, Issue 11, 2010, Pages 2545-2551

  Schäbitz, Wolf R ^a   Laage, Rico ^b   Vogt, Gerhard ^b   Koch, Winfried ^j   Kollmar, Rainer ^c   Schwab, Stefan ^c   Schneider, Dietmar ^d   Hamann, Gerhard F ^e   Rosenkranz, Michael ^f   Veltkamp, Roland ^g   Fiebach, Jochen B ^h   Hacke, Werner ^a   Grotta, James C ^k   Fisher, Marc ⁱ   Schneider, Armin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SYGNIS Bioscience   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j HaaPACS GmbH   (Germany)

^k UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

clinical trial; granulocyte colony stimulating factor; hematopoietic growth factor; leukocytes

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRACARDIAC THROMBOSIS; MALE; MIDDLE CEREBRAL ARTERY; MONOCYTE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUTROPHIL; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE PATIENT; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOCYTES; MALE; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

EID: 78149294383     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.579508     Document Type: Article

References (13)

1. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hemato-poietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115:2083-2098.
2. Schabitz WR, Schneider A. New targets for established proteins: Exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci. 2007;28:157-161.
3. Minnerup J, Heidrich J, Wellmann J, Rogalewski A, Schneider A, Schabitz WR. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke. 2008; 39:1855-1861.
4. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577-581.
5. Schneider A, Wysocki R, Pitzer C, Kruger C, Laage R, Schwab S, Bach A, Schabitz WR. An extended window of opportunity for G-CSF treatment in cerebral ischemia. BMC Biol. 2006;4:36.
6. Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR. Toward a multimodal neuroprotective treatment of stroke. Stroke. 2006;37: 1129-1136.
7. Fischmeister G, Kurz M, Haas OA, Micksche M, Buchinger P, Printz D, Ressmann G, Stroebel T, Peters C, Fritsch G, Gadner H. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: Comparison of efficacy and tolerability. Ann Hematol. 1999;78:117-123.
8. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC, German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: Development and external validation of prognostic models. Stroke. 2004;35:158-162.
9. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colony-stimulating factor for acute ischemic stroke: A randomized controlled trial. CMAJ. 2006;174:927-933.
10. Sprigg N, Bath PM, Zhao L, Willmot MR, Gray LJ, Walker MF, Dennis MS, Russell N. Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: The stem cell trial of recovery enhancement after stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke. 2006;37: 2979-2983.
11. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006; 113:2105-2112.
12. Sehara Y, Hayashi T, Deguchi K, Zhang H, Tsuchiya A, Yamashita T, Lukic V, Nagai M, Kamiya T, Abe K. Decreased focal inflammatory response by G-CSF may improve stroke outcome after transient middle cerebral artery occlusion in rats. J Neurosci Res. 2007;85:2167-2174.
13. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, Prass K, Meisel A. Stroke-induced immunodepression: Experimental evidence and clinical relevance. Stroke. 2007;38:770-773.